Zante Greg Files Viking Therapeutics (VKTX) Form 4 - July 28, 2026

Transactions (2)

About Viking Therapeutics Inc.

Viking Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapies for metabolic and endocrine disorders. Headquartered in San Diego, California, Viking concentrates on mechanism-driven drug candidates targeting obesity, metabolic liver disease, and rare genetic conditions. Its lead program, VK2735, is being advanced in both subcutaneous and oral formulations as a dual agonist of GLP-1 and GIP receptors for the potential treatment of obesity and related metabolic disorders. Viking also develops VK2809, a selective thyroid hormone receptor beta agonist aimed at lipid and broader metabolic disorders, and VK0214, a similar class molecule targeting X-linked adrenoleukodystrophy, a rare neuro-metabolic disease. In addition, the company is progressing internally developed dual amylin and calcitonin receptor agonists for obesity and other metabolic conditions. Operating as a single business segment centered on research and clinical development, Viking Therapeutics plays a specialized role in the healthcare and biotechnology market by supplying a focused pipeline of metabolic and endocrine drug candidates to address areas of significant unmet medical need.